Public Health - Overdose and Infectious Disease Prevention Services Program
SB83 authorizes the Maryland Department of Health, in consultation with local health departments, to approve up to six community-based Overdose and Infectious Disease Prevention Services Programs statewide. These programs would operate at single sites in areas with high drug use and, to the extent practicable, be distributed across urban, suburban, and rural areas. Eligible operators include a broad range of community-based organizations such as hospitals, clinics, substance use treatment centers, federally qualified health centers, mental health facilities, local health departments, and faith-based organizations.
The bill requires approved programs to provide supervised locations where people can consume preobtained drugs, sterile supplies, disposal services, overdose monitoring and response, naloxone access, and referrals to treatment and health services. Required referrals and education include substance use disorder counseling, HIV and hepatitis testing, reproductive health services, wound care, overdose prevention, and safe syringe disposal. Programs may bill insurance for covered services with consent, accept grants and donations, coordinate with existing outreach and syringe service programs, and use mobile facilities, but may not be located in residentially zoned areas.
SB83 would add a new subtitle to the Health-General Article establishing a limited pilot-style framework for overdose and infectious disease prevention services in Maryland. It creates a new approval process for the Department of Health, sets operating standards, provides legal protections from arrest, prosecution, civil or administrative penalties, and property seizure for authorized participants, and requires annual reporting to the department and legislative committees. The act is temporary, taking effect July 1, 2025 and expiring June 30, 2029 unless reenacted.
The bill’s structure suggests a public health-oriented approach focused on harm reduction, overdose prevention, and linkage to treatment rather than punishment. Even without recorded committee testimony or votes in the provided materials, the bill’s detailed safeguards, reporting requirements, and limited number of authorized sites indicate an effort to balance public health goals with oversight and geographic distribution. The overall tone of the legislation is cautious but supportive of expanding overdose prevention services.
The main points of contention are likely to center on the authorization of supervised consumption services, which allow individuals to consume preobtained drugs under supervision, and the bill’s legal immunity provisions for users, staff, and property owners. Opponents may object to the perception that the state is facilitating illegal drug use, while supporters are likely to emphasize overdose reversal, infectious disease prevention, and referrals to treatment. Additional debate may arise over site location restrictions, the cap of six programs, and whether such services should be concentrated in high-need areas or expanded more broadly.